Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
May 21 2024 - 9:59AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
May, 2024
Commission File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes
¨ No x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED (Registrant) |
|
|
Date: May 21, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit
99.1
|
Dr.
Reddy’s Laboratories Ltd.
8-2-337,
Road No. 3, Banjara Hills,
Hyderabad
- 500 034, Telangana,
India.
CIN
: L85195TG1984PLC004507
Tel
: +91 40 4900 2900
Fax :
+91 40 4900 2999
Email
: mail@drreddys.com
www.drreddys.com |
May
21, 2024
National
Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE
Limited (Scrip Code: 500124)
New
York Stock Exchange Inc. (Stock Code: RDY)
NSE
IFSC Ltd. (Stock Code: DRREDDY)
Dear
Sir/Madam,
Ref:
|
Disclosure
under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
This
is to inform that the wholly-owned subsidiary of the Company, namely, Aurigene Oncology Limited (formerly, Aurigene Discovery Technologies
Limited) [hereinafter referred to as “Aurigene”], has received an order from GST Authority towards tax demand including penalty.
The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:
Name
of the authority |
: |
Assistant
Commissioner of Commercial Taxes, Madhapur, Hyderabad, Telangana. |
Nature
and details of the action(s) taken, initiated or order(s) passed |
: |
Aurigene,
a wholly-owned subsidiary of the Company has received order seeking demand including penalty under Section 73 of the TGST & CGST
Acts, 2017. |
Date
of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority |
: |
Order
dated April 30, 2024 was received by the Authorized person of the Company on May 21, 2024. |
Details
of the violation(s)/ contravention(s) committed or alleged to be committed |
: |
The
authority has passed the order on the contention that correct tax liability was not declared while filing the annual returns of GSTR-09. |
Impact
on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible |
: |
The
above order levies a penalty of Rs. 64,94,862/-. Based on our evaluation, there is no material impact on the financials, operations,
or other activities of the Company. |
Aurigene
will evaluate filing necessary appeal with the appellate authority in this regard.
This
is for your information and records.
Thanking
you.
Yours
faithfully,
For
Dr. Reddy’s Laboratories Limited
K
Randhir Singh
Company
Secretary, Compliance Officer & Head-CSR
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From May 2024 to Jun 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Jun 2023 to Jun 2024